{"analyses":[{"ciLowerLimit":"0.432","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.276","estimateComment":"The hazard ratio was estimated using Cox regression. The hazard ratio is relative to BORT + P.","groupDescription":"The null hypothesis was that there was no difference between the 2 treatment groups. The alternative hypothesis was that progression-free survival was longer in the BORT + BV group. Stratified Analysis.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.2804","paramType":"Hazard Ratio (HR)","paramValue":"0.743","statisticalComment":"The analysis was stratified for number of prior cancer treatments (1, \\> 1) and β2-microglobulin level (\\< 3.5, ≥ 3.5 mg/L).","statisticalMethod":"Log Rank"},{"ciLowerLimit":"0.424","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.200","estimateComment":"Hazard ratio relative to BORT + P was estimated using Cox regression.","groupDescription":"Unstratified Analysis.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.2009","paramType":"Hazard Ratio (HR)","paramValue":"0.713","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"4.17","upperLimit":"7.20","value":"5.1"},{"groupId":"OG001","lowerLimit":"4.40","upperLimit":"8.54","value":"6.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"53"},{"groupId":"OG001","value":"49"}],"units":"Participants"}],"description":"Progression-free survival (PFS) was defined as the time from randomization to disease progression or death on study from any cause within 30 days of the last response assessment. Disease progression was determined by the investigator using the International Myeloma Working Group's (IMWG) uniform response criteria. Median PFS was estimated using Kaplan-Meier methodology. For patients who were alive at the time of the analysis and whose disease had not yet progressed, PFS was censored at the time of the last response assessment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received bortezomib 1.3 mg/m\\^2 administered as a 3- to 5-second bolus intravenous injection on Days 1, 4, 8, and 11 of a 21-day cycle for a maximum of eight cycles and placebo intravenous infusion on the first day of each 21-day cycle during the blinded treatment phase. At the completion of the 8-cycle treatment phase, participants entered the observation phase until disease progression.","id":"OG000","title":"BORT + P"},{"description":"Participants received bortezomib 1.3 mg/m\\^2 administered as a 3- to 5-second bolus intravenous injection on Days 1, 4, 8, and 11 of a 21-day cycle for a maximum of eight cycles and bevacizumab 15 mg/kg administered by intravenous infusion on the first day of each 21-day cycle during the blinded treatment phase. After completion of 8 cycles, participants could continue to receive bevacizumab as monotherapy until disease progression.","id":"OG001","title":"BORT + BV"}],"paramType":"MEDIAN","populationDescription":"Randomized Patients","reportingStatus":"POSTED","timeFrame":"From randomization to disease progression or death on study (up to 116 weeks).","title":"Progression-free Survival (PFS)","type":"PRIMARY","unitOfMeasure":"months"}